News | August 19, 2024
CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
The emergence of new infections in India is a growing concern
The emergence of new infections in India is a growing concern
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Our centers are performing as expected or even better
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Subscribe To Our Newsletter & Stay Updated
